Loading
A phase 3 trial of Selinexor and Ruxolitinib in myeloproliferative neoplasms, run by Karyopharm Therapeutics Inc, active and no longer recruiting.
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis is a phase 3 interventional study registered as NCT04562389 by Karyopharm Therapeutics Inc, with 353 participants enrolled, started 2021-03-11 and due to reach its primary completion in 2026-02-20. Interventions recorded: Selinexor and Ruxolitinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Ruxolitinib, Primary myelofibrosis and the tag pipeline.
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/